Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mingxing Pharma's Hemodialysis Concentrate Powder (A Powder and B Powder) is a two-component system used to prepare dialysate for hemodialysis in patients with acute or chronic renal failure. Powder A (acidic concentrate) typically contains sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and an organic acid (such as acetic or citric acid), often with glucose. Powder B (basic concentrate) consists of sodium bicarbonate. When dissolved and mixed in specific ratios with highly purified water by a hemodialysis machine, these components form a balanced electrolyte solution that facilitates the removal of metabolic waste products and excess fluid from the patient's blood while maintaining electrolyte and acid-base homeostasis. In China, these products are regulated as pharmaceuticals (国药准字).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hemodialysis concentrate powder A + hemodialysis concentrate powder B.